24 results
8-K
EX-99.1
TCRX
Tscan Therapeutics Inc
13 May 24
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:15am
purposes.
The Company announced two upcoming poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May … medical meetings:
oAmerican Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
oAmerican Association for Cancer Research (AACR) Annual Meeting
8-K
EX-99.2
TCRX
Tscan Therapeutics Inc
16 Apr 24
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
4:16pm
60 40 40 25 25 10 20 20 ? 0 0 0 HPV16 MAGE-C2 MAGE-A4 PRAME MAGE-A1 HPV16 MAGE-C2 MAGE-A4 PRAME MAGE-A1 Source: American Cancer Society 35
8-K
EX-99.1
TCRX
Tscan Therapeutics Inc
6 Mar 24
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood
8-K
TCRX
Tscan Therapeutics Inc
11 Dec 23
Regulation FD Disclosure
8:00am
and TSC-101 at the 65th American Society of Hematology (“ASH”) Annual Meeting and Exposition. The Company will host a virtual KOL event on Monday, December
8-K
EX-99.1
d0x ko1m9vl33aa
11 Dec 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
mluv80ooo9o evk5fp
9 Nov 23
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:15am
8-K
EX-99.1
n1jlsnhvdmt12ueem
10 Aug 23
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:15am
424B5
rsn dc1lan7wdoi7s
26 May 23
Prospectus supplement for primary offering
8:12pm
424B5
ict3iy9xhk
25 May 23
Prospectus supplement for primary offering
4:59pm
8-K
EX-99.1
hur9ac9bi4
17 May 23
Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation
8:15am
8-K
tisz1
17 May 23
Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation
8:15am
8-K
EX-99.1
imf4ubn wd6q0b3a6
10 May 23
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:16am
8-K
EX-99.1
fby2dc323a5ezri4
9 Nov 22
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:06am
8-K
EX-99.1
mbop5x9wxcy75lu79
10 Aug 22
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
12:00am
8-K
gouk9a91
7 Jul 22
Departure of Directors or Certain Officers
7:11am
8-K
EX-99.1
5izuxe2gm5p31qqyx
9 May 22
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones
7:08am
10-K
ksi80uq0a6evwd6ocs
9 Mar 22
Annual report
7:30am